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Available online 24 April 2014Abstract The MB49 bladder cancer cell vaccine was effective against bladder cancer in the mice model in previous studies.
However, part of the tumors regrew as the vaccine could not eliminate the cancer stem cells (CSCs). MB49 bladder cancer stem
cells (MCSCs) were isolated by a combination of the limited dilution method and the serum free culture medium method. MCSCs
possessed higher expression of CD133, CD44, OCT4, NANOG, and ABCG2, the ability of differentiation, higher proliferative abilities,
lower susceptibility to chemotherapy, greater migration in vitro, and stronger tumorigenic abilities in vivo. Then streptavidin–
mouse granulocyte macrophage–colony stimulating factor (SA–mGM–CSF) MCSCs vaccine was prepared. SA–mGM–CSF MCSCs
vaccine extended the survival of the mice and inhibited the growth of tumor in protective, therapeutic, memorial and specific
immune response experiments. The level of immunoglobulin G and the ratio of dendritic cells and CD4+ and CD8+ T cells were
highest in the experimental group when compared to those in other four control groups, as well as for the cytotoxicity assay. We
demonstrated that SA–mGM–CSF MCSCs vaccine induces an antitumor immune response to metastatic bladder cancer.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Bladder cancer is one of the most common urologic cancers
in the United States and the rest of the world (Siegel et al.,
2013), and radical cystectomy with pelvic lymphadenectomy⁎ Corresponding author. Fax: +86 20 61641762.
E-mail address: tanwanlong@gmail.com (W. Tan).
1 Contributed equally to this work.
http://dx.doi.org/10.1016/j.scr.2014.04.006
1873-5061/© 2014 The Authors. Published by Elsevier B.V. This
(http://creativecommons.org/licenses/by-nc-nd/3.0/).is the standard treatment for this kind of cancer. However,
more than half of the patients will develop local or
metastatic recurrence (Cagiannos and Morash, 2009). In
previous studies, we have shown that the MB49 bladder
cancer cell vaccine induces a specific antitumor immunity
and is efficiently effective against metastatic bladder
cancer in a mice model (Shi et al., 2013; Zhang et al.,
2011, 2012). However, we also found that over time part of
the tumors experienced regression and regrew because the
cancer stem cells (CSCs) could not be eliminated by theis an open access article under the CC BY-NC-ND license





CD133 F: 5′-CGGGATCCGAAAAACTGATCTGT-3′ 615 bp
R: 5′-CCGCTCGAGTTACCTAGTTACTCT
CTCC-3′







OCT4 F: 5′-TCAGCCAAACGACCATCTGC-3′ 205 bp
R: 5′TTCTCCAGGTTGCCTCTCAC-3′
GAPDH F: 5′-CCATGGAGAAGGCTGGGG-3′ 198 bp
R: 5′-CAAAGTTGTCATCCATGACC-3′
112 Y. Zhu et al.vaccine. Relapses of solid tumors may be attributed to the
inability of traditional chemotherapies and radiotherapies to
eradicate CSCs (McDermott and Wicha, 2010). Our former
vaccine was unable to induce specific immunities responsi-
ble for eliminating CSCs. Therefore, on the basis of our
protein-anchor technology, we developed a vaccine that
displayed streptavidin–mouse granulocyte macrophage–col-
ony stimulating factor (SA–mGM–CSF) on the surface of
biotinylated MB49 bladder cancer stem cells (MCSCs), and
evaluated the antitumor effects of this vaccine in the
treatment of MCSCs in a metastatic mouse model.
Materials and methods
Establishment of MCSCs
MB49, a mouse bladder cancer cell line, was a gift from Dr. I.
C. Summerhayes from the Lahey Clinic in Burlington,
Massachusetts (Shi et al., 2013; Zhang et al., 2011, 2012).
MB49 cells were cultured in RPMI1640 containing 10% fetal
bovine serum (FBS, Thermo Scientific HyClone, Logan, Utah)
at 37 °C in a 5% CO2 humidified incubator.
The optimal serum free culture medium (SFM) consisted
of RPMI1640, epidermal growth factor (20 ng/ml), basic
fibroblast growth factor (20 ng/ml), leukemia inhibitory
factor (20 ng/ml), B-27 serum-free supplement (20 μl/ml),
and bovine serum albumin (4 μg/ml).
For the limited dilution method, MB49 cells were digested
with accutase-enzyme cell detachment medium (Accutase,
eBioscience, San Diego, California) and the number of cells
was counted using a counting chamber. Cell suspensions were
diluted with SFM in a ten-fold manner until the terminal
density of the cells was 5 cells/ml. Finally, 200 μl of cell
suspension was plated into 96-well plates with ultra low
attachment surface (Corning Life Sciences, Union City,
California), and single cells were marked and observed daily.
Most cells were unable to proliferate in SFM, only a small
percentage of cells generated clone spheres. These single
cells extracted from MB49 cells were called passage 1 MCSCs.
Several passage 1 single cells were cultured in SFM, and
the supernatant was removed and supplemented with fresh
SFM every 5–7 days. By day 30, single cells had grown into
large, visible, single-cell spheres. Spheres were digested
with Accutase, dispersed mechanically, and cultured in
24-well plates with ultra low attachment surface (Corning
Life Sciences) before forming passage 2 cells.
Passage 2 cells were supplemented with fresh SFM every
3–4 days. By day 15, most cells had grown into visible
spheres that were collected, centrifuged, digested, dis-
persed, and cultured in 6-well plates with ultra low
attachment surface (Corning Life Sciences) before forming
passage 3 cells. Cells were expanded in T25 culture flasks
(Corning Life Sciences) through multiple passages using the
same protocol.
Characterizations of MCSCs
Expression of MCSCs markers
Flow cytometry (FCM). MB49 cells and MCSCs were har-
vested respectively. They were dissociated at a density of1 × 104 cells in 100 μl autoMACS running buffer (Miltenyi
Biotec, Bergisch Gladbach, Germany), labeled with PE mouse
anti-prominin-1 (Miltenyi Biotec) and FITC mouse antiCD44
(Miltenyi Biotec), incubated at 4 °C for 20 min, and washed
twice with phosphate buffered saline (PBS). PE rat IgG1 κ
isotype control (eBioscience) and TITC rat IgG2b κ isotype
control (eBioscience) were used as negative control. The ratio
of CD44+CD133+ cells was evaluated using a BD FACSAria cell
sorter (Becton-Dickinson, San Jose, California).
Quantitative polymerase chain reaction (qPCR). Total RNA
was extracted using the Arcturus PicoPure RNA isolation kit
(Applied Biosciences, Carlsbad, New Mexico). RNA quality
was verified by the Bioanalyzer RNA Pico Chip (Agilent
Technologies, Santa Clara, California). Two micrograms of
total RNA were reverse transcribed with Superscript III
(Invitrogen, Grand Island, New York). cDNA was amplified
with SYBR green PCR master mix (Bio-Rad, Hercules,
California) on a 7500 real time PCR system (AB Applied
Biosystems, Singapore). Cycling conditions were 95 °C for
10 s (denaturation) and 60 °C for 60 s (annealing and
extension). Primer sequences are listed in Table 1. Normal-
ization and fold changes were calculated using the ΔΔCt
method, and GAPDH was used as negative control.
Western blotting (WB). Proteins were separated by 10%
sodium dodecyl sulfate–polyacrylamide gel and transferred
to polyvinylidene difluoride membranes (Millipore, Billerica,
Massachusetts) electrophoretically. Filters were blocked
with 5% skim milk in PBS and incubated at 4 °C overnight
with the primary antibody anti-OCT4 (Abcam, Cambridge,
Massachusetts), anti-NANOG (Abcam), anti-ABCG2 (Abcam),
or anti-β-actin antibody (Abcam). Filters were then incu-
bated with conjugated anti-mouse secondary antibodies
(Abcam). Protein bands were detected by Fluor Chem FC2
(Alpha Innotech, San Leandro, California), and the intensi-
ties of protein blots were analyzed by Image Lab software.
Differentiation
MCSCs were collected, dissociated into single cells, and
cultured in RPMI1640 supplementedwith 10% FBS that induced
113MB49 CSCs against metastatic bladder cancercell differentiation. Meanwhile, MCSC spheres were cultured
by the same method.Functional comparison
Cell proliferation assay. Cells were plated in the optimal
SFM at a number of 1 × 103 cells per well in a 96-well plate
and incubated for 1, 2, 3, 4, 5, or 6 days respectively. Then
10 μl of cell counting kit-8 reagent (CCK-8, Dojindo
Molecular Technologies, Kumamoto, Japan) was added at a
fixed time of the day. After 4 hours of incubation, the
absorbance value was measured at 450 nm using an EnSpire
2300 multilabel reader (PerkinElmer, Singapore).
Soft agar assay. Cells were resuspended at a density of
1 × 104 cells/ml in 0.66% bottom agar (Beyotime, Jiangsu,
China) supplemented with 10% FBS, and on the top 1.32%
agar was layered supplemented with 20% FBS in 6-well plates
respectively. Plates were incubated for three weeks. Finally
the colonies with diameters greater than 50 μm were
counted.
Migration abilities in vitro. Cells (1 × 104 cells/well) were
seeded in pure RPMI1640 (0.25 ml) in the upper well of a
6.5-mm pore-size polycarbonate membrane chamber inserted
in a transwell apparatus (Costar, Cambridge, Massachusetts).
RPMI1640 medium containing 10% FBS (0.75 ml) was added
in the lower well. Cells were incubated for 24 hours and
cells that had migrated to the bottom surface of the insert
were fixed in paraformaldehyde for 20 min, stained in
Giemsa for 15 min, rinsed in PBS, and inspected via
inverted microscopy.
Resistance to chemotherapy abilities. Cells were seeded
at a number of 1 × 104 per well in a 96-well plate. After
24 hours, mitomycin (Sigma, Saint Louis, Missouri), cisplatin
(Sigma), paclitaxel (Sigma), or doxorubicin (Sigma) was
added with different concentrations (Table 2) respectively,
and cells were treated for a subsequent 96 hours. Then
CCK-8 reagent was added to each well, and after 4 hours of
incubation, the absorbance values were measured. Cell
viability was expressed as the percentage of absorbance
values of the treated wells related to the absorbance of the
untreated control wells.
Tumorigenic abilities in vivo. All experimental procedures
with animals have been given prior approval by the Ethics
Committee of the Southern Medical University under
Contract 2011016. Four-week-old nude mice (Center of
Experimental Animals, Southern Medical University, Guang-
zhou, China) were maintained and treated under specific,Table 2 Concentrations of chemotherapeutic agents.
Agents Concentrations
Paclitaxel 10 nM 100 nM 1 μM 10 μM
Doxorubicin 10 nM 100 nM 1 μM 10 μM
Cisplatin 5 μM 10 μM 15 μM 20 μM
Mitomycin 10 μM 80 μM 640 μM 5.12 mMpathogen-free conditions. Cells were injected subcutane-
ously into nude mice at a number of 1 × 104 cells in MCSCs
and 1 × 106 cells in MB49 cells, respectively. Each group had
5 mice. Tumor xenograft formation was observed every
week. At the end of 8 weeks, mice were sacrificed by
cervical dislocation. Tumor engrafts were removed, and the
volume of the tumors was measured using the formula
d2 × D/2, where d and D were the smallest and the largest
diameters respectively (Zhang et al., 2012).
Preparation of SA–mGM–CSF MCSCs vaccine
Vaccine preparation
MCSCs were fixed in 30% ethanol for 30 min at room
temperature. Ethanol-fixed MCSCs were incubated at a
number of 1 × 106 cells with 1 mM fresh EZ-Link Sulfo-NHS-
LC-Biotin (Pierce Biotechnology, Rockford, Illinois) for
1 hour at room temperature, and washed 3 times with PBS.
The biotinylated cells were incubated with SA–mGM–CSF
fusion protein which was prepared in our lab (Hu et al.,
2010), and washed 3 times with PBS. Therefore, the product
was called SA–mGM–CSF MCSCs vaccine.
Evaluation of SA–mGM–CSF on the surface of MCSCs
The SA–mGM–CSF MCSCs vaccine was washed with PBS and
labeled with FITC anti-mGM–CSF monoclonal antibody (BD
Biosciences Pharmingen, San Diego, California) for 30 min at
room temperature. The biotinylated cells were used as a
control group. The presence of SA–mGM–CSF on the surface
of MCSCs was evaluated using a BD FACSAria cell sorter.
Bioactive assay of SA–mGM–CSF immobilized on the
surface of MCSCs
The vaccine was lysed by three freeze thaw cycles. The
membrane fractions were harvested by centrifugation at
15,000 g at 4 °C for 5 min and resuspended in complete
medium. The SA–mGM–CSF bioactivity was assessed by
proliferation of bone marrow cells (BMCs), and SA–green
fluorescent protein (GFP) was used as a control group. The
membrane fractions were added to BMCs in a 96-well
plate, and incubated at 37 °C in a 5% CO2 humidified
incubator for 3 days. Cell viability was measured by the
CCK-8 assay.
Level of GM–CSF on SA–mGM–CSF MCSCs vaccine
The level of GM–CSF antibody on the vaccine was measured
by WB as described previously. The primary antibodies were
anti-GM–CSF (Abcam) and anti-beta II tubulin (Abcam), and
SA–GFP was used as a control group.
Animal experiment
Subcutaneous and lung metastatic mouse model of MCSCs
C57BL/6 female mice were injected with 1 × 105 MCSCs into
the hind leg to make a subcutaneous model. Mice were
injected intravenously in the tail vein with 2 × 104 MCSCs to
make a pulmonary model.
Protective immune response experiment
All mice from the pulmonary and subcutaneous model were
divided into five groups and each group had 15 mice,
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MCSCs vaccine. The other four control groups were received
SA–mGM–CSF MB49 cells vaccine, ethanol-fixed MCSCs, SA–
mGM–CSF or PBS.
Healthy mice were injected subcutaneously with 1 × 105
SA–mGM–CSF MCSCs vaccines on days 0, 4 and 8, followed by
injection with MCSCs on day 12 to prepare a subcutaneous or
pulmonary model as described previously. The volume of
subcutaneous tumors was measured like before. The survival
state was observed daily, and the survival time was recorded
until day 60.Immunotherapy experiment
All mice in the pulmonary and subcutaneous model were
divided into five groups and each group had 15 mice as
described above. Subcutaneous and lung metastatic model
mice were established respectively as described previously.
They were injected subcutaneously with 1 × 105 SA–mGM–
CSF MCSCs vaccines on days 0, 4, 8 and 12. The volume of
subcutaneous tumors and the survival state was observed
the same as before.
Tumor-specific lymphocyte cytotoxicity assay. On day 19
of the immunotherapy experiment, splenocytes were isolat-
ed and stimulated by the inactivated MCSCs plus hIL-2 (R&D
systems, Minneapolis, Minnesota) for 5 days. Splenocytes
served as effector cells, and MCSCs served as target cells.
Both cells were seeded in a 96-well plate at the desired
effector/target cells ratio. After 4 hours of incubation, the
supernatant was collected. Then the lactate dehydrogenase
activity was measured by cytotox 96 non-radioactive cytotox-
icity assay (Promega, Madison, Wisconsin). The percentage of
tumor-specific cytotoxic T lymphocytes (CTL) was calculated
as follows: percentage of CTL = (experimental −effector
spontaneous − target spontaneous) / (target maximum −
target spontaneous) × 100%.
Enzyme-linked immunosorbent assay (ELISA) for serum
Immunoglobulin G (IgG) antibodies. On day 19 of the
immunotherapy experiment, 100 μl blood was collected and
congealed for 20 min at room temperature. Then the
supernatant was harvested by centrifugation at 3000 rpm
for 5 min. The concentrations of IgG were examined with an
ELISA kit (Abcam) according to the manufacturer's protocol.
The optical density (OD) value was measured at 450 nm with
a microplate reader.
FCM of dendritic cells (DCs). On day 19 of the immuno-
therapy experiment, splenocytes were isolated, and red
blood cells were lysed by FCM lysing solution (Santa Cruz,
Dallas, Texas). Splenocytes were labeled with FITC anti-
mCD80 (Biolegend, San Diego, California) and PE anti-
mCD11c (Biolegend) using the manufacturer's instruction.
The ratio of CD11c+CD80+ cells was evaluated using a BD
FACSAria cell sorter.
FCM of T cell subsets. On day 19 of the immunotherapy
experiment, blood was collected and stained simulta-
neously with PE anti-mCD4 (eBioscience) and FITC anti-
mCD8 (eBioscience). Then red blood cells were lysed
by FCM lysing solution and centrifuged. The ratio of CD4+and CD8+ cells was evaluated using a BD FACSAria cell
sorter.
Immunohistochemistry. Sections (4 μm thick) were cut onto
polylysine-coated microscope slides. After deparaffinization in
xylene and hydration through graded alcohol, sections were
washed and then exposed with ready-to-use proteinase K
solution to enhance antigenicity. Endogenous peroxidase was
inactivated by 3% hydrogen peroxide for 5 min and non-specific
binding was blocked with 5% normal goat serum in PBS for
15 min. Then sections were incubated at 37 °C for 1 hour with
anti-GM–CSF (Abcam) at a 1:100 dilution. After washing with
PBS, sections were incubated with anti-mouse secondary
antibody (Abcam), followed by incubation with HRP conjugated
streptavidin. Finally, sections were colored using DAB, washed
in running tap water and counterstained with hematoxylin and
mounted.
Memory immune response experiment
On day 60 after tumor challenge, the tumor-free mice from
the subcutaneous group or the survived mice from the lung
metastatic group were injected intravenously in the tail vein
with 1 × 105 MCSCs again. The untreated mice were used as
a negative control, and each group had 10 mice. The survival
time was recorded.
Specific immune response experiment
On day 60 of the immunotherapy experiment, 5 tumor-free
mice or the survived mice were injected subcutaneously
with MCSCs in the right hind leg and RM-1 cells in the left
hind leg. The volume of subcutaneous tumors was measured.
Statistical analysis
SPSS19.0 software was used for statistical evaluation. All
numeric data was expressed as the mean value ± standard
deviation. The statistical analysis was performed by one-way
ANOVA (when more than 3 groups) or Students t-test
(between 2 groups). The survival rates were analyzed using
the Kaplan–Meier method, and the log-rank test was used to
compare the difference in survival rate between groups.
Differences between the values were considered statistically
significant when P b 0.05.
Results
Establishment of MCSCs in SFM
The limited dilution method showed that only 2–3% of MB49
cells generated CSC spheres in SFM. A passage 1 single MB49
cell formed a CSC sphere within 30 days in SFM (Fig. 1A).
MCSCs from several single cells were passaged after 15 days
to form new tumor spheres, and most MCSCs generated
secondary spheres. (Fig. 1B)
Characterizations of MCSCs
Expression of CSCs markers
As demonstrated by FCM analysis, the fraction of CD44+ cells
in MB49 cells was higher than in MCSCs, and MCSCs events
Figure 1 The morphology of MCSCs. (A) A representative image of a cancer stem cell sphere formation originating from a single
MB49 cell in SFM. (B) MCSCs generated secondary passages (d = day; P = passage).
115MB49 CSCs against metastatic bladder cancercollected were smaller on account of the difficulty in
proliferation. However, the fraction of CD133+CD44+ cells
was 19.83 ± 0.68% in MCSCs and 3.57 ± 0.38% in MB49 cells,
which was elevated in MCSCs relative to MB49 cells (Fig. 2A).Figure 2 Comparison of specific markers between MCSCs and MB4
representative image of CD44+CD133+ cells in FCM analysis. (right panel)
those in MB49 cells in FCM analysis. (B) In qPCR analysis, the expres
expression was higher in MB49 cells. (C) (left panel) The pattern of OCT4
a positive control. (right panel) In WB analysis, OCT4, NANOG and ABCG2The relative levels of CD133, OCT4 and NANOG mRNA
were respectively 5.2, 4.6 and 4.0 times higher in MCSCs
when compared with MB49 cells. However, the level of CD44
was higher in MB49 cells (Fig. 2B).9 cells using (A) FCM, (B) qPCR and (C) WB. (A) (left panel) The
The fraction of CD44+CD133+ cells in MCSCs was more elevated than
sion of CD133, OCT4 and NANOG was higher in MCSCs, and CD44
, NANOG and ABCG2 expression in WB analysis. β-Actin was used as
were abundantly expressed in MCSCs. ⁎⁎⁎P b 0.001 (vs. MB49 cells).
116 Y. Zhu et al.OCT4, NANOG and ABCG2 were all expressed in MCSCs
and MB49 cells as demonstrated by WB assay. They were
sparsely distributed in MB49 cells, but they were abundantly
expressed in MCSCs (Fig. 2C).
Differentiation
MCSCs were globular and floating in SFM. When MCSCs were
reseeded in medium containing 10% FBS, they became flat
after being differentiated and attached to the culture dish.
This morphology resembled the morphology of MB49 cells.
The morphology of MCSCs was reverse differentiation to that
of MB49 bladder cancer cells (Fig. 3).
Functional comparison
CCK-8 assay showed that MCSCs displayed an increased
proliferation rate when compared with MB49 cells in SFM on
day 4, 5, 6 (Fig. 4A). The soft agar assay revealed that MCSCs
formed bigger and more numerous colonies than MB49 cells
did (Fig. 4B). Compared with MB49 cells, both assays showed
that MCSCs possessed highly proliferative abilities, either
they did not differentiate in the optimal SFM or differenti-
ated to MB49 cells in the medium containing FBS.
More invaded MCSCs were observed when compared to
MB49 cells under the same incubation conditions (Fig. 4C). The
transwell migration assay displayed that MCSCs contained
higher transmembrane activity than MB49 cells.
Compared to MB49 cells, MCSCs showed higher cell
viabilities after being treated with different concentrations
of mitomycin, cisplatin, paclitaxel or doxorubicin (Fig. 4D).Figure 3 The morphology of MCSCs was reverse differentiation to
(d = day).MCSCs demonstrated lower susceptibility to all four tradi-
tional anticancer agents.
MCSCs caused a more remarkable tumor volume than MB49
cells did despite the same number of injections (Fig. 4E).
Compared with MB49 cells, the histological appearance by
hematoxylin and eosin staining displayed greater cell density
and deeper nuclear staining in xenograft tumor sections
formed by MCSCs (Fig. 4F). Xenograft formation showed that
MCSCs possessed strong tumorigenic ability in vivo.
Preparation of SA–mGM–CSF MCSCs vaccine
As demonstrated by FCM analysis, the percentage of MCSCs
anchored with SA–mGM–CSF was 89.5 ± 1.5% (Fig. 5A). The
membrane bound mGM–CSF stimulated the proliferation of
BMCs in a dosage dependent manner which was demonstrat-
ed by using the CCK-8 assay (Fig. 5B). The level of GM–CSF
antibody on the vaccine was abundantly expressed as
displayed by WB assay (Fig. 5C). These results demonstrated
that SA–mGM–CSF could be efficiently anchored on the
surface of MCSCs and retain its bioactivity.
Animal experiment
Protective immune response with SA–mGM–CSF
MCSCs vaccines
Pulmonary model mice in the treated group had a signifi-
cantly longer survival rate (median of 49 days) when
compared to the mice in the four control groups. Thethat of MB49 cells when cultured in medium containing 10% FBS
Figure 4 Functional comparisons between MCSCs and MB49 cells in (A and B) proliferative abilities, (C) migrational abilities,
(D) anti-cancer chemotherapy abilities, and (E and F) tumorigenic abilities. (A) MCSCs contain higher absorbance value at days 4, 5,
and 6 in cell proliferation assay. (B) (left panel) The light images of soft agar assay. (right panel) MCSCs formed more numerous
colonies than MB49 cells. (C) (left panel) The light images of transwell migration assay. (right panel) The numbers of invaded MCSCs
were higher than MB49 cells. (D) Compared to MB49 cells, MCSCs showed higher cell viabilities after treatment with various
concentrations of anti-cancer drugs including paclitaxel, doxorubicin, cisplatin and mitomycin. (E) (left panel) The light images of
subcutaneously tumorigenicity by xenograft formation in nude mice. (right panel) MCSCs caused remarkable bigger tumor volume
than MB49 cells. (F) Microphotographs of H&E stained tumor tissue sections displayed greater cell density and deeper nuclear staining
in xenograft tumor sections formed by MCSCs. ⁎P b 0.05, ⁎⁎P b 0.01, ⁎⁎⁎P b 0.001 (vs. MB49 cells).
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ethanol-fixed MCSCs, SA–mGM–CSF or PBS groups were 42,
34, 35 or 30 days, respectively (Fig. 6A).
The tumors from the subcutaneous model mice in the
treated group reached a maximum mean volume of
181 mm3, and had a significantly smaller tumor volume
trend when compared to the four control groups. The
maximum mean volume of the four control groups was 430,
662, 705 and 931 mm3, respectively (Fig. 6B).
Immunotherapy with SA–mGM–CSF MCSCs vaccines
The survival of mice from the pulmonary model in the
treated group was significantly longer when compared to
those in the four control groups. This also applied for thetumor size in the subcutaneous model (Fig. 6CD). Similar
with previous protective immune response, the treated
group had the longest survival and the smallest tumor
volume.
Tumor-specific lymphocyte cytotoxicity assays. The per-
centage of CTL in the treated group was significantly higher
when compared to the four control groups (Fig. 7A). These
results demonstrated that SA–mGM–CSF vaccine could estab-
lish a stronger tumor-specific T-cell immunity.
Detection of serum IgG antibodies. The level of specific
IgG antibodies in the serum of the treated group was more
obvious than in the serum of the four control groups
Figure 6 The antitumor potency of SA–mGM–CSF MCSCs vaccine in (A and B) protective, (C and D) therapeutic, (E) memorial and
(F) specific immune response experiment. (A, C, and E) Pulmonary model mice in treated group had a significantly longer survival
compared to the control groups. (B, D, and F) Subcutaneous model mice in treated group had a significantly smaller tumor volumes
trend compared to the control groups. #P N 0.05; ⁎⁎⁎P b 0.001 (vs. treated group).
Figure 7 The antitumor potency of SA–mGM–CSF MCSCs vaccine using (A) cytotoxicity assay, (B) ELISA and (C and D) FCM. (A) Both
in pulmonary model mice (left panel) and subcutaneous model mice (right panel), the percentage of CTL in treated group was
significantly higher compared to the control groups. (B) The level of specific IgG antibodies in sera in the treated group was increased
when compared to the four control groups in pulmonary model mice (left panel) and subcutaneous model mice (right panel).
(C) Analysis by FCM, (left panel) the representative image of DCs (CD11c+CD80+ cells) in pulmonary model mice (up panel) and
subcutaneous model mice (down panel). In both model mice, (right panel) the number of DCs in the treated group was more elevated
than those in the control groups. (D) Analysis by FCM, (left panel) the representative image of CD4+ and CD8+ T cells in pulmonary
model mice (up panel) and subcutaneous model mice (down panel). In both model mice, (right panel) the number of CD4+ and CD8+ T
cells in the treated group was more elevated than those in the control groups. ⁎⁎⁎P b 0.001 (vs. treated group).
Figure 5 Analysis of SA–mGM–CSF MCSCs vaccine by (A) FCM, (B) CCK-8 and (C) WB assays. (A) The representative image of MCSCs
anchored with SA–mGM–CSF. (B) SA–mGM–CSF MCSCs vaccine contained higher absorbance value in proliferative activity, while SA–
GFP was the control group. (C) The pattern of GM–CSF expression in WB analysis. β-Tublin was used as a positive control. ⁎⁎P b 0.01,
⁎⁎⁎P b 0.001 (vs. SA–GFP group).
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120 Y. Zhu et al.(Fig. 7B). The increase of IgG could strengthen the antitumor
immunity effect in mice.
Number of DCs. As shown by FCM analysis, the number of
mature DCs (CD11c+CD80+) was significantly more in the
treated group than in the four control groups (Fig. 7C).
Results demonstrated that SA–mGM–CSF MCSCs vaccine
could increase the mature DCs population.
Number of T cell subsets. As demonstrated by FCM
analysis, the proportion of CD4+ and CD8+ T cells in the
treated group was increased when compared with the four
control groups (Fig. 7D). The increase of CD4+ and CD8+ T
lymphocytes could enhance the antitumor immunity effect
in mice.
Expression of GM–CSF in subcutaneous tumor. As testified
by immunohistochemistry, the expression of GM–CSF could
be found in sections from subcutaneous tumors from the
treated group, and showed significant differences when
compared with sections from the four control groups (Fig. 8).
Memory immune response with SA–mGM–CSF MCSCs
vaccines
The survival time of mice in the experimental group was
significantly longer than in the control group after a second
challenge of MCSCs (Fig. 6E). This result demonstrated that
SA–mGM–CSF MCSCs vaccine could produce long term
memory immunity to MCSCs.
Specific immune response with SA–mGM–CSF MCSCs
vaccines
The volume of the tumors at MCSCs injecting side in the right
leg was obviously smaller than that at the RM-1 cell injecting
side in the left leg (Fig. 6F). This result demonstrated that
SA–mGM–CSF MCSCs vaccine could establish a strong tumor
specific T cell immunity.
Discussion
The present study examined the feasibility and efficacy of an
active vaccine immunotherapy targeting CSCs. To our
knowledge, this is the first report of a therapy targeting a
characterized population of CSCs in bladder cancer (Vik-Mo
et al., 2013).
The limited dilution method showed that only a small
percentage of MB49 cells generated CSC spheres, and this
proportion was similar to other published results (She et al.,
2008). The origin of MCSCs in this study was derived from
several single cells. To facilitate the transition of MCSCs to
cells suitable for vaccine applications, advances in expandingFigure 8 The expression of GM–CSF in histologicMCSCs have become an absolute necessity. There are three
methods that have been used to isolate CSCs from tumors:
specific cell surface markers, SFM, and side population cells
(Li et al., 2012). Considering that serum caused irreversible
differentiation of stem cells, SFM selection might be useful for
CSCs expansion and would allow for the maintenance of an
undifferentiated stem cell status (Yanamoto et al., 2011).
CD133 and CD44 have been used to identify CSCs from
other cancer tissues (Brescia et al., 2012; Han et al., 2011).
However, CD44 cannot be regarded as a universal bladder
cancer stem cell marker (Hatina and Schulz, 2012), and the
fraction of CD44+ cells in MCSCs was lower as well.
Interestingly, our results showed an elevated CD44+CD133+
expression in MCSCs. Targeting CD133+ and CD44+ cancer
cells or the pathways sustaining CD44+CD133+ subpopulation
might be an efficient strategy for colorectal cancer therapy
(Ou et al., 2013). CD44+CD133+ both positive cells might be a
CSC-enriched populations in MB49 bladder cancer cells. Only
cells expressing CD44+CD133+ would be counted as MCSCs by
FCM. OCT4 plays a significant role in self-renewal (Felthaus
et al., 2011), and NANOG is identified as a key molecule to
maintain self-renewal and to block differentiation (Gong et
al., 2012). These genes can potentially lead to tumorigenesis
and affect some cancer behaviors, such as resistance to
therapies or cancer recurrence (Li et al., 2012). They were
upregulated not only at the protein level (WB) but also at the
mRNA transcript level (qPCR) in MCSCs.
The capability to differentiate is another important
feature of CSCs (Bentivegna et al., 2010). MCSCs in different
culture conditions showed changed differentiation features.
Furthermore, we applied techniques to functionally charac-
terize the MCSCs populations (Dalerba et al., 2007; Visvader
and Lindeman, 2008). MCSCs had typical CSCs' characteriza-
tions that were capable of self-regeneration with a higher
proliferative capacity and a greater colony forming potential.
MCSCs showed greater capacity to penetrate wells, which
indicated that these cells were the most likely to migrate.
Chemotherapy kills the majority of cells in a tumor, but it
does not kill CSCs, which might be the mechanism behind the
resistance to chemotherapy (Sung et al., 2008; Okamoto et
al., 2009). MCSCs had a lower susceptibility to mitomycin,
cisplatin, paclitaxel, and doxorubicin. ATP-binding cassette
(ABC) transporters explained the mechanism that many
chemical drugs were pumped out of cells by ABC trans-
porters (Scopelliti et al., 2009). MCSCs showed a higher level
of ABCG2 expression at the protein level (WB), and the
upregulation of ABCG2 was associated with the resistance of
MCSCs to anti-cancer drugs. The standard experimental
method for the isolation of CSCs was used to test the
tumorigenicity of cancer cells in immunodeficient mice
(Lobo et al., 2007). MCSCs showed the greatest ability to
form tumors in subcutaneous tissues of nude mice. Takenal sections by immunohistochemistry analysis.
121MB49 CSCs against metastatic bladder cancertogether, these data showed that cultured MCSCs displayed
specific CSC properties.
Although SA–mGM–CSF MB49 cells vaccine in earlier
studies induced a specific antitumor immunity to MB49
cells and obliterated the tumor, vaccine could not induce
specific immunity responsible for MCSCs. Therefore, some
mice still got tumors after a period of time. In order to kill
MCSCs, SA–mGM–CSF MCSCs vaccine was developed on the
basis of original vaccine.
Compared with the original vaccine, the SA–mGM–CSF
MCSCs vaccine efficiently prolonged the survival of the mice
and inhibited the tumor growth. Furthermore, the mice
cured by vaccine could resist a second attack of MCSCs but
not RM-1 cells, and effector cells also inhibited MCSCs
growth which was showed by using a cytotoxicity assay in
vitro. The level of IgG in the serum reflected the level of
total Ig as it accounted for more than 80% of total Ig. This
study showed that the level of IgG increased significantly in
the treated group when compared with the control groups.
These results indicated that the vaccine immunotherapy
could induce tumor specific immunity against MCSCs.
GM–CSF could motivate mature DCs from immature cells
(Fleetwood et al., 2005), and plays a decisive role in the
development of DCs in the immune response. However, the
impact of anticancer immunity rests with the action of T
lymphocytes. DCs are intermediates of T lymphocytes immu-
nity and the most effective antigen presenting cells (Hong et
al., 2012). The vaccine brought about a T lymphocyte
mediated immune response, such as the increase in CD4+ and
CD8+ T cells and the reaction of effector T cells aiming at CSCs
(Weng et al., 2013). The vaccine based on CD4+ T cell would
stimulate standing functional CTL memory via CD40L (Xie et
al., 2013). So CD4+ and CD8+ T lymphocytes cells are the main
effector cells in antitumor immunity. The vaccine filled with
CSCs antigens could lead to a robust antitumor T cell immunity
(Pellegatta et al., 2006). Therefore, mGM–CSF, DCs and T
lymphocytes have a close relationship with the antitumor
response. MCSCs can be identified and killed by CD4+ and CD8+
T lymphocytes, and immunosuppressive effects of MCSCs can
be overcome in mice tumor models.
Conclusion
In this study, a therapeutic MCSCs vaccine was successfully
generated and used to obliterate MCSCs to prevent tumor
regrowth. However, the exact mechanism is still unknown.
More clarity of the functional manner could promote its
clinical use. A vaccine made up of patient specific antigens
or general cancer antigens may be the direction for the
development of a clinical available vaccine in the future.
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